bioihbjkbjnl/mcl2 huggingface dataset:
The Quality of Recovery After General Anesthesia With Desflurane and Sevoflurane in Endoscopic Ureteral Lithotripsy
Condition: Anesthesia
Study type: Interventional

Summary: 
      The good quality of recovery after general anesthesia is one of goals for short procedures
      and ambulatory surgeries. The study's objective was to compare the quality of recovery after
      general anesthesia with desflurane and sevoflurane with laryngeal mask airway for endoscopic
      ureteral lithotripsy.
    

Detailed description: 
      This is a randomized controlled trial. There were 60 cases of endoscopic ureteral lithotripsy
      under general anesthesia with laryngeal mask airway were enrolled. All cases were randomly
      divided into two group (desflurane or sevoflurane). Each group had 30 cases. Primary outcome
      was time to awakening. Secondary outcomes were time to wash-out of volatile anesthetics, time
      to extubation, irritation after awakening, and modified Aldrete score.

      Statistical analysis was performed by using Kaplan-Meieir curve and log-rank test for time to
      adequate depth of anesthesia and time to awakening; t-test for time to wash-out of volatile
      anesthetics; chi-square test for depth of anesthesia by PRST score, irritation after
      awakening and Aldrete score; Fisher test for adverse effects of volatile anesthetics.

      The research was approved by Gia Dinh People Hospital ethics committee
    

Intervention name(s): Other
Intervention type(s): Other
Intervention description(s): Compare time to awakening and quality of recovery after general anesthesia between two groups.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
RCT Comparing 21 and 22 G Needle in the Diagnosis of Sarcoidosis by EBUS TBNA
Condition: Sarcoidosis
MeSH terms: Sarcoidosis
Study type: Interventional

Summary: 
      Randomized controlled trial to determine the efficacy of different needles sizes (22G and
      21G) used in endobronchial ultrasound guided transbronchial needle aspiration
    

Detailed description: 
      Among the bronchoscopic techniques in diagnosis of sarcoidosis, transbronchial needle
      aspiration (TBNA) of lymph nodes has emerged as a particularly useful supplement to the
      previously known endobronchial and transbronchial biopsies. The efficacy and safety of
      conventional TBNA is well established. With improvements in technology, the last decade has
      seen the use of convex probe endobronchial ultrasonography (EBUS) to guide TBNA under direct
      vision. This technique is a minimally invasive alternative to mediastinoscopy, further it
      offers additional advantage of choosing the appropriate node for sampling on the basis of
      their echogenicity. Studies subsequently have demonstrated the superiority of EBUS TBNA over
      conventional TBNA.

      Once the role of TBNA in diagnostic bronchoscopy was established, technical aspects of the
      procedure became the topic of research. Needle size used in TBNA is one such important
      factor. Apparently, larger the needle, better the tissue yield and hence improved diagnostic
      capability. Conventional TBNA is usually performed with a 19G needle, though varying sizes
      have been used in different studies (18, 21, 22, 26G). On the other hand, EBUS-TBNA is
      performed with a 22G needle. More recently 21G needles are being used for the same purpose.
      There have been conflicting reports in literature, when these two needle sizes have been
      compared with regards to the adequacy of the sample, accuracy of diagnosis and the rate of
      complications. Moreover, the above studies undertaken so far were done from centers where
      malignancy was the predominant diagnosis. Whether the needle size used during EBUS TBNA has
      any impact on diagnosing benign diseases like sarcoidosis is still not clear, hence this
      study was planned. The investigators hypothesize that performing EBUS-TBNA using 21G needles
      may enable identification of intact compact granulomas in sarcoidosis, and hence a better
      diagnostic yield than using a 22G needle.
    

Intervention name(s): 21 G needle group; 22 G needle group
Intervention type(s): Other; Other
Intervention description(s): Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment; Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Diagnostic
H - Test Usage in Identification of Sexual Orientation Among People.
Condition: Sexual Behavior; Sexual Orientation Conflict Disorder; Sexual Arousal Disorder; Sexual Orientation; Sexual; Orientation, Relationship Disorder
MeSH terms: Sexual Dysfunctions, Psychological
Study type: Interventional

Summary: 
      Using of H - test in identifying the sexual behavior of the human.
    

Detailed description: 
      The test using videos and in the same time watching the vital signs of the participant to
      identify any changes in them align with the vides.

      These videos contain +18 contents that can excite them and make them sexually active. So we
      can determine with type of vides that more excited to the human and select his or her sexual
      behavior type.
    

Intervention name(s): H - Test
Intervention type(s): Diagnostic Test
Intervention description(s): Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.
Other intervention name(s): Sexual desire test; Sexual health test
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary purpose: Diagnostic
Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy
Condition: Spondyloarthritis; Ultrasonography
MeSH terms: Spondylitis; Spondylarthritis
Study type: Observational

Summary: 
      Patients with spondylarthritis (SpA) (including ankylosing spondylitis, psoriatic arthritis,
      arthritis as part of inflammatory bowel disease and reactive arthritis) have axial
      involvement (the spine) as well as peripheral inflammation in joints and entheses (where the
      tendons and ligaments are anchored to the bone). Patients with high disease activity of SpA
      may need biological treatment (anti-TNF alpha), which are very expensive medications. Thus it
      is necessary to have a sensitive method for assessing the response to treatment.
      Ultrasonography (US) is a validated and reliable method for assessing disease activity in
      joints and tendons, and may be used to follow the treatment response.

      The present study will include patients with SpA starting on anti-TNF alpha treatment (as
      first biologic medication or when switching to a new biologic treatment). The study is an
      extension of the ongoing NORDMARD study (Norwegian longitudinal observational study of
      arthritic patients starting disease-modifying treatment). The patients will be examined by
      use of US of 38 joints and 14 entheses at baseline and after 3, 6 and 12 months.

      The objectives are to explore US as a method to assess peripheral inflammatory activity for
      evaluation of response to medication as well as to compare the US pathology with clinical and
      laboratory findings.
    


Intervention name(s): Anti-TNF alpha therapy
Intervention type(s): Biological
Intervention description(s): All medical treatment will be standardizes following good medical practice
Other intervention name(s): Adalimumab (HumiraR); Etanercept (EnbrelR); Infliximab (RemicadeR); Golimumab (SimponiR)
Intervention MeSH terms: Adalimumab; Infliximab; Golimumab; Etanercept
Observational model: Case-Only
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        SpA patients with high disease activity
      
Biospecimen description: 
      At the first visit, one glass with blood will be frozen for later genetical analyzes, all
      related to questions regarding SpA.
    
Keywords: SpA; Anti-TNF alpha treatment; Ultrasonography; Synovitis; Enthesitis
Phase I Clinical Trial of DA-6886 in Healthy Male Subjects
Condition: Irritable Bowel Syndrome
MeSH terms: Irritable Bowel Syndrome
Study type: Interventional
Phase: Phase 1

Summary: 
      DA-6886_IBS_I is a phase I, dose block-randomized, double-blind, placebo-controlled,
      single/multiple dosing, dose escalation clinical trial with open-labelled food effect study
      of single dose to investigate the safety, tolerability and pharmacokinetics of DA-6886 after
      oral administration in healthy male subjects.
    


Intervention name(s): DA-6886; Placebo of DA-6886
Intervention type(s): Drug; Drug
Intervention description(s): single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)
multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation); DA-6886 placebo
Allocation: Randomized
Intervention model: Factorial Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain
Condition: Peripheral Neuropathic Pain
MeSH terms: Neuralgia
Study type: Interventional
Phase: Phase 3

Summary: 
      A Randomized, Double-blind, Active-Controlled, Multi-center, Phase 3 Trial to Compare the
      Safety and Efficacy between YHD1119 and Pregabalin in Patients with Peripheral Neuropathic
      Pain
    


Intervention name(s): YHD1119; Lyrica
Intervention type(s): Drug; Drug
Intervention description(s): YHD1119 150mg, PO YHD1119 300mg, PO
YHD1119 600mg, PO; Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
Other intervention name(s): Pregabalin; Pregabalin
Intervention MeSH terms: Pregabalin
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions
Condition: Coronary Arteriosclerosis
MeSH terms: Arteriosclerosis; Coronary Artery Disease; Myocardial Ischemia
Study type: Interventional

Summary: 
      To evaluate the safety, efficacy and deliverability of the Combo bio-engineered
      sirolimus-eluting stent versus the Nano polymer-free sirolimus- eluting stents in the
      treatment of patients with de novo stenotic lesions of native coronary artery.
    

Detailed description: 
      This is a prospective, multi-center, open-label, non-inferiority, randomized controlled trial
      which plans to enroll 436 subjects. All subjects enrolled will be randomly assigned to the
      test group (n=218) and the control group (n=218). Subjects in the test group and the control
      group will receive Combo stents and Nano stents respectively.
    

Intervention name(s): OrbusNeich Combo stent™; sirolimus-eluting stent system
Intervention type(s): Device; Device
Intervention description(s): The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
Other intervention name(s): Nano Polymer-free sirolimus-eluting stent system
Intervention MeSH terms: Sirolimus; Temsirolimus; MTOR Inhibitors
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: intracoronary stent; drug eluting stent; sirolimus; endothelial progenitor cells
Effects of Oxygen Status on Hypoxia Inducible Factor 1-α and Inflammation. A Pilot Proof of Principle Study.
Condition: Hypoxia; Hyperoxia
MeSH terms: Hypoxia; Hyperoxia
Study type: Interventional
Phase: Phase 1

Summary: 
      It has been shown in in vitro and animal models that hypoxia can have pro-inflammatory
      effects and hyperoxia can have anti-inflammatory effects. The pro-inflammatory effect could
      be the result of activation of Hypoxia Inducible Factor, a transcription factor that is known
      to activate many cell systems aimed at cell survival, including the inflammatory response.
      The anti-inflammatory effects of hyperoxia could be the annihilation of Hypoxia Inducible
      Factor, but also a decrease in inflammation due to oxygen toxicity resulting in a decrease in
      clearance of pathogens. These effects have been sparsely studied in humans. Therefore, we
      hypothesize that hypoxia results in an increase in Hypoxia Inducible Factor in circulating
      leukocytes and increases inflammatory reactions, whereas hyperoxia decreases these reactions.
    


Intervention name(s): Hypoxia; Hyperoxia
Intervention type(s): Other; Other
Intervention description(s): Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.; Subjects will be breathing 100% oxygen
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Basic Science
Keywords: Oxygen; Hypoxia; Hyperoxia; Inflammation; Innate immunity
Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in Bangladesh
Condition: Polio
MeSH terms: Poliomyelitis
Study type: Interventional

Summary: 
      Hypothesis:

      The immunogenicity of oral polio vaccine (OPV) will be enhanced in Bangladeshi infants who
      receive bicarbonate buffer at the time of polio immunization.
    

Detailed description: 
      The investigators will conduct a study to evaluate the impact of administering bicarbonate
      buffer on the serologic responses to oral polio vaccine (OPV) in Bangladeshi infants.
    

Intervention name(s): Buffer
Intervention type(s): Other
Intervention description(s): 5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Magnesium Food Frequency Questionnaire
Condition: Healthy
Study type: Observational

Summary: 
      The study aims to develop a quick tool to assess magnesium intakes.
    

Detailed description: 
      The study aims to develop a quick tool to assess magnesium intakes. Participants will be
      asked to record a complete dietary intake for 14 consecutive days, the magnesium food
      frequency questionnaire along with a calcium food frequency questionnaire, and a brief
      participant data form. Data from the 14 day consecutive food diary will be correlated with
      the food frequency questionnaire.
    

Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Healthy men and women ages 20-75 years free of chronic diseases.
The Impact of SCN9A Gene Polymorphism on Individual Pain Perception in the General Population
Condition: Pain; Surgery
Study type: Observational

Summary: 
      This study was conducted to explore whether the non-synonymous single-nucleotide
      polymorphisms in SCN9A gene can predict individual basal pain perception and postoperative
      pain intensity in the general population undergoing upper abdominal surgery. Methods:
      Patients receiving elective upper abdominal surgery under general anesthesia were recruited
      into this study. Genotyping of SCN9A was carried out by direct sequencing. The investigators
      measured their preoperative pressure pain threshold (PPT) and pressure pain tolerance (PTO).
      The visual analog scale (VAS) was used for pain evaluation at rest during patient-controlled
      analgesia (PCA) treatment 0 h, 12 h ,24 h and 48h after operation. And the PCA press
      frequency and drug consumption were recorded.
    

Detailed description: 
      Patients with the following diseases were excluded: known history of chronic pain,
      psychiatric diseases or communication disorders, diabetes mellitus, severe cardiovascular
      diseases, kidney or liver diseases with poor hepatic function, alcohol or drug abuse, heavy
      smoker, pregnancy or at the lactation period.
    

Sampling method: Non-Probability Sample
Study population: 
        800 Chinese patients receiving elective upper abdominal surgery under general anesthesia
      
Biospecimen description: 
      Heparin anti-coagulated blood (2 ml) was collected from the central venous during the
      operation and all blood samples were stored at -80℃. Genomic DNA was extracted from the blood
      samples using a guanidinium isothiocyanate method.
    
Keywords: gene polymorphism; SCN9A; pain perception; postoperative pain
Prospective Randomized Double Blind Clinical Trial of Polyhexamethylene Biguanide Impregnated Foam Dressing
Condition: Wounds
Study type: Interventional
Phase: Phase 2

Summary: 
      This is a multi-center, prospective, randomized, double blind, pilot clinical trial of
      subjects with chronic wounds. The purpose of this study is to compare the efficacy of COPA
      AMD PHMB Impregnated foam dressing compared to regular foam dressing in subjects with chronic
      wounds.
    


Intervention name(s): COPA AMD (note: name is not an acronym); COPA (note: name is not an acronym)
Intervention type(s): Device; Device
Intervention description(s): Foam dressing impregnated with Polyhexamethylene Biguanide; Regular foam dressing without PHMB
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Transcranial Direct/ Alternating Current Stimulation for Parkinson's Disease Treatment
Condition: Parkinson Disease; tACS; tDCS
MeSH terms: Parkinson Disease
Study type: Interventional

Summary: 
      To investigate the difference in the treatment efficacy between transcranial direct current
      stimulation and transcranial alternating current stimulation on Parkinson's disease,
      including the improvements in the motor, cognitive, and underlying neural mechanisms behind
      differences in efficacy by electroencephalography (EEG).
    

Detailed description: 
      All patients underwent a medical evaluation that include physical examinations and routine
      laboratory studies before and after stimulation sessions. Patients were randomly allocated to
      tACS, tDCS, and sham groups. There are about 20 patients in each group. Allocation was by
      computer generating random numbers. The decision to enroll a patient was always made prior to
      randomization. Patients were studied using a double-blind design. Study participants,
      clinical raters, and all personnel responsible for the clinical care of the patient remained
      masked to allocated conditions and allocation parameters. Only stimulation administrators had
      access to the randomization list; they had minimal contact with the patients, and no role in
      assessing the UPDRS(Unified Parkinson´s Disease Rating Scale), Hoehn & Yahr, and
      MoCA(Montreal Cognitive Assessment). Each patient would be treated for 20 minutes of
      transcranial electrical stimulation.

      Before the stimulation session, UPDRS, Hoehn & Yahr, and MoCA were obtained by a trained
      investigator to assess the baseline severity of symptoms. The patients received
      electroencephalography (EEG) recorded during resting state for 5 minutes.

      During the stimulation session, patients were asked to perform simple reaction tasks at the
      same time.

      After the stimulation session, UPDRS, Hoehn & Yahr, and MoCA were obtained, as well as the
      Global Index of Safety（tES slide effects） to assess adverse events of the treatment. The
      patients also received a measure of electroencephalography (EEG) recorded during the resting
      state and a simple reaction task.
    

Intervention name(s): tACS; tDCS; sham
Intervention type(s): Device; Device; Device
Intervention description(s): used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as the stimulation electrode, while the return electrode placed on the right shoulder . The dose was at 2mA, 20Hz for 20 minutes.; used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 2mA for 20 minutes.; used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 0mA for 20 minutes with the ramp up and down time of 40 seconds.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients
Condition: Hypercholesterolemia
MeSH terms: Hypercholesterolemia
Study type: Observational

Summary: 
      Inflammation plays a major role in atherosclerosis. Pentraxin 3 (PTX3) a multifunctional
      pattern-recognition protein, is expressed in many tissues/cells, including innate immunity
      cells, endothelium and atherosclerotic plaques. Its role is controversial: it may exert
      protective cardiovascular effects and/or it may be an indicator of plaque vulnerability and
      future cardiovascular risk.

      LDL-Apheresis removes apoB100-containing lipoproteins and it can prevent progression of
      coronary artery disease (CAD). LDL-Apheresis exerts non-lipidic beneficial effects on the
      procoagulatory state and on hemorheology. No data exist about the effects of LDL-Apheresis on
      plasma PTX3 levels.
    

Detailed description: 
      Hypercholesterolemic patients with documented CAD, on chronic fortnightly LDL-apheresis
      treatment will be enrolled in this study.

      Blood samples will be collected before and after a single LDL-Apheresis treatment to asses
      PTX3, HsCRP, IL6, IL10, Fibrinogen and lipid plasma levels.
    

Intervention name(s): LDL-apheresis
Intervention type(s): Procedure
Intervention description(s): The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
Other intervention name(s): HELP-apheresis
Observational model: Case-Only
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Hypercholesterolemic patients with documented CAD, on cronic fortnightly HELP-apheresis
        treatment.
      
Biospecimen description: 
      serum and plasma
    
Keywords: Hypercholesterolemia; LDL-apheresis; Coronary artery disease; PTX3; CRP; IL6; IL10